Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

An inhibitor of oxidative phosphorylation exploits cancer vulnerability.

Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, McAfoos T, Morlacchi P, Ackroyd J, Agip AA, Al-Atrash G, Asara J, Bardenhagen J, Carrillo CC, Carroll C, Chang E, Ciurea S, Cross JB, Czako B, Deem A, Daver N, de Groot JF, Dong JW, Feng N, Gao G, Gay J, Do MG, Greer J, Giuliani V, Han J, Han L, Henry VK, Hirst J, Huang S, Jiang Y, Kang Z, Khor T, Konoplev S, Lin YH, Liu G, Lodi A, Lofton T, Ma H, Mahendra M, Matre P, Mullinax R, Peoples M, Petrocchi A, Rodriguez-Canale J, Serreli R, Shi T, Smith M, Tabe Y, Theroff J, Tiziani S, Xu Q, Zhang Q, Muller F, DePinho RA, Toniatti C, Draetta GF, Heffernan TP, Konopleva M, Jones P, Di Francesco ME, Marszalek JR.

Nat Med. 2018 Jun 11. doi: 10.1038/s41591-018-0052-4. [Epub ahead of print]

PMID:
29892070
2.

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.

Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. doi: 10.1093/jnen/nly022.

3.

Implementing paediatric early warning scores systems in the Netherlands: future implications.

de Groot JF, Damen N, de Loos E, van de Steeg L, Koopmans L, Rosias P, Bruijn M, Goorhuis J, Wagner C.

BMC Pediatr. 2018 Apr 6;18(1):128. doi: 10.1186/s12887-018-1099-6.

4.

Multi-center study finds postoperative residual non-enhancing component of glioblastoma as a new determinant of patient outcome.

Kotrotsou A, Elakkad A, Sun J, Thomas GA, Yang D, Abrol S, Wei W, Weinberg JS, Bakhtiari AS, Kircher MF, Luedi MM, de Groot JF, Sawaya R, Kumar AJ, Zinn PO, Colen RR.

J Neurooncol. 2018 Apr 4. doi: 10.1007/s11060-018-2850-4. [Epub ahead of print]

PMID:
29619649
5.

The polo-like kinase 1 inhibitor volasertib synergistically increases radiation efficacy in glioma stem cells.

Dong J, Park SY, Nguyen N, Ezhilarasan R, Martinez-Ledesma E, Wu S, Henry V, Piao Y, Tiao N, Brunell D, Stephan C, Verhaak R, Sulman E, Balasubramaniyan V, de Groot JF.

Oncotarget. 2018 Jan 8;9(12):10497-10509. doi: 10.18632/oncotarget.24041. eCollection 2018 Feb 13.

6.

Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma.

Piao Y, Henry V, Tiao N, Park SY, Martinez-Ledesma J, Dong JW, Balasubramaniyan V, de Groot JF.

Oncotarget. 2017 Jun 29;8(57):96970-96983. doi: 10.18632/oncotarget.18859. eCollection 2017 Nov 14.

7.

A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma.

Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP.

Oncotarget. 2017 Oct 12;8(52):90488-90495. doi: 10.18632/oncotarget.21799. eCollection 2017 Oct 27.

8.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

PMID:
29074604
9.

Stabilization of phosphofructokinase 1 platelet isoform by AKT promotes tumorigenesis.

Lee JH, Liu R, Li J, Zhang C, Wang Y, Cai Q, Qian X, Xia Y, Zheng Y, Piao Y, Chen Q, de Groot JF, Jiang T, Lu Z.

Nat Commun. 2017 Oct 16;8(1):949. doi: 10.1038/s41467-017-00906-9.

10.

Wheelchair Shuttle Test for Assessing Aerobic Fitness in Youth With Spina Bifida: Validity and Reliability.

Bloemen MAT, de Groot JF, Backx FJG, Benner J, Kruitwagen CLJJ, Takken T.

Phys Ther. 2017 Oct 1;97(10):1020-1029. doi: 10.1093/ptj/pzx075.

11.

Treatment of Glioblastoma.

Nam JY, de Groot JF.

J Oncol Pract. 2017 Oct;13(10):629-638. doi: 10.1200/JOP.2017.025536. Review.

PMID:
29020535
12.

Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma.

Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, Kent TA, de Groot JF.

Neuro Oncol. 2018 Jan 10;20(1):113-122. doi: 10.1093/neuonc/nox144.

PMID:
29016865
13.

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ.

Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Review.

PMID:
28925994
14.

Development of a wheelchair mobility skills test for children and adolescents: combining evidence with clinical expertise.

Sol ME, Verschuren O, de Groot L, de Groot JF; Fit-For-the-Future!-consortium.

BMC Pediatr. 2017 Feb 13;17(1):51. doi: 10.1186/s12887-017-0809-9. Review.

15.

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS.

J Clin Oncol. 2017 Apr 20;35(12):1341-1367. doi: 10.1200/JCO.2016.71.5292. Epub 2017 Feb 1. No abstract available.

PMID:
28148207
16.

Cell Signaling Pathways in Brain Tumors.

Harrison RA, de Groot JF.

Top Magn Reson Imaging. 2017 Feb;26(1):15-26. doi: 10.1097/RMR.0000000000000112. Review.

PMID:
28079711
17.

Fitkids Treadmill Test: Age- and Sex-Related Normative Values in Dutch Children and Adolescents.

Kotte EM, de Groot JF, Bongers BC, Winkler AM, Takken T.

Phys Ther. 2016 Nov;96(11):1764-1772. Epub 2016 May 19.

PMID:
27197825
18.

Validity and Reliability of Skill-Related Fitness Tests for Wheelchair-Using Youth With Spina Bifida.

Bloemen MA, Takken T, Backx FJ, Vos M, Kruitwagen CL, de Groot JF.

Arch Phys Med Rehabil. 2017 Jun;98(6):1097-1103. doi: 10.1016/j.apmr.2016.08.469. Epub 2016 Sep 12.

19.

Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

O'Neill AF, Qin L, Wen PY, de Groot JF, Van den Abbeele AD, Yap JT.

J Neurooncol. 2016 Dec;130(3):495-503. Epub 2016 Aug 30.

PMID:
27576699
20.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

21.

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.

Weathers SP, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK, Tremont-Lukats I, Colen RR, Yung WKA, de Groot JF.

J Neurooncol. 2016 Sep;129(3):487-494. doi: 10.1007/s11060-016-2195-9. Epub 2016 Jul 12.

22.

Periostin (POSTN) Regulates Tumor Resistance to Antiangiogenic Therapy in Glioma Models.

Park SY, Piao Y, Jeong KJ, Dong J, de Groot JF.

Mol Cancer Ther. 2016 Sep;15(9):2187-97. doi: 10.1158/1535-7163.MCT-15-0427. Epub 2016 Jun 15.

23.

Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.

Mandel JJ, Cachia D, Liu D, Wilson C, Aldape K, Fuller G, de Groot JF.

J Neurooncol. 2016 Aug;129(1):147-54. doi: 10.1007/s11060-016-2157-2. Epub 2016 Jun 7.

24.

Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a/p27 in glioblastoma.

Park SY, Piao Y, Thomas C, Fuller GN, de Groot JF.

Oncotarget. 2016 May 3;7(18):26793-805. doi: 10.18632/oncotarget.8471.

25.

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.

Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF.

Neuro Oncol. 2016 Sep;18(9):1230-41. doi: 10.1093/neuonc/now030. Epub 2016 Mar 9.

26.

ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.

Gatson NT, Weathers SP, de Groot JF.

CNS Oncol. 2016;5(1):11-26. doi: 10.2217/cns.15.38. Epub 2015 Dec 15. Retraction in: CNS Oncol. 2016;5(2):110.

PMID:
26670466
27.

A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.

Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M.

J Neurooncol. 2016 Jan;126(2):309-16. doi: 10.1007/s11060-015-1966-z. Epub 2015 Oct 27.

28.

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M.

Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8.

29.

Validity and Reproducibility of a New Treadmill Protocol: The Fitkids Treadmill Test.

Kotte EM, DE Groot JF, Bongers BC, Winkler AM, Takken T.

Med Sci Sports Exerc. 2015 Oct;47(10):2241-7. doi: 10.1249/MSS.0000000000000657.

PMID:
26378949
30.

Interferon-regulatory factor-1 (IRF1) regulates bevacizumab induced autophagy.

Liang J, Piao Y, Henry V, Tiao N, de Groot JF.

Oncotarget. 2015 Oct 13;6(31):31479-92. doi: 10.18632/oncotarget.5491.

31.

Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.

Cachia D, Kamiya-Matsuoka C, Mandel JJ, Olar A, Cykowski MD, Armstrong TS, Fuller GN, Gilbert MR, De Groot JF.

J Neurooncol. 2015 Nov;125(2):401-10. doi: 10.1007/s11060-015-1930-y. Epub 2015 Sep 9.

PMID:
26354773
32.

Cardiopulmonary Exercise Testing in Children and Adolescents With Dystrophinopathies: A Pilot Study.

Bartels B, Takken T, Blank AC, van Moorsel H, van der Pol WL, de Groot JF.

Pediatr Phys Ther. 2015 Fall;27(3):227-34. doi: 10.1097/PEP.0000000000000159.

PMID:
26102164
33.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

34.

Adult brainstem gliomas: Correlation of clinical and molecular features.

Theeler BJ, Ellezam B, Melguizo-Gavilanes I, de Groot JF, Mahajan A, Aldape KD, Bruner JM, Puduvalli VK.

J Neurol Sci. 2015;353(1-2):92-7. doi: 10.1016/j.jns.2015.04.014. Epub 2015 Apr 18.

35.

Personal and environmental factors to consider when aiming to improve participation in physical activity in children with Spina Bifida: a qualitative study.

Bloemen MA, Verschuren O, van Mechelen C, Borst HE, de Leeuw AJ, van der Hoef M, de Groot JF.

BMC Neurol. 2015 Feb 10;15:11. doi: 10.1186/s12883-015-0265-9.

36.

Arm cranking versus wheelchair propulsion for testing aerobic fitness in children with spina bifida who are wheelchair dependent.

Bloemen MA, de Groot JF, Backx FJ, Westerveld RA, Takken T.

J Rehabil Med. 2015 May;47(5):432-7. doi: 10.2340/16501977-1944.

37.

High-grade gliomas.

de Groot JF.

Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):332-44. doi: 10.1212/01.CON.0000464173.58262.d9. Review.

PMID:
25837899
38.

Seek and destroy: relating cancer drivers to therapies.

Martinez-Ledesma E, de Groot JF, Verhaak RG.

Cancer Cell. 2015 Mar 9;27(3):319-21. doi: 10.1016/j.ccell.2015.02.011.

39.

Validation of an activity monitor for children who are partly or completely wheelchair-dependent.

Nooijen CF, de Groot JF, Stam HJ, van den Berg-Emons RJ, Bussmann HB; Fit for the Future Consortium.

J Neuroeng Rehabil. 2015 Feb 6;12:11. doi: 10.1186/s12984-015-0004-x.

40.

Factors associated with physical activity in children and adolescents with a physical disability: a systematic review.

Bloemen MA, Backx FJ, Takken T, Wittink H, Benner J, Mollema J, de Groot JF.

Dev Med Child Neurol. 2015 Feb;57(2):137-48. doi: 10.1111/dmcn.12624. Epub 2014 Nov 18. Review.

41.

Antiangiogenic therapy for glioblastoma: current status and future prospects.

Batchelor TT, Reardon DA, de Groot JF, Wick W, Weller M.

Clin Cancer Res. 2014 Nov 15;20(22):5612-9. doi: 10.1158/1078-0432.CCR-14-0834. Review.

42.

Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma.

Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, Aldape KD, Yung WK, Gilbert MR; MD Anderson Community Clinical Oncology Program; Brain Tumor Trials Collaborative.

Neuro Oncol. 2015 Feb;17(2):266-73. doi: 10.1093/neuonc/nou155. Epub 2014 Sep 19.

43.

Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution.

Mandel JJ, Yust-Katz S, Cachia D, Wu J, Liu D, de Groot JF, Yung AW, Gilbert MR.

J Neurooncol. 2014 Dec;120(3):597-605. doi: 10.1007/s11060-014-1592-1. Epub 2014 Aug 29.

PMID:
25168214
44.

Prolonged survival in adult neurofibromatosis type I patients with recurrent high-grade gliomas treated with bevacizumab.

Theeler BJ, Ellezam B, Yust-Katz S, Slopis JM, Loghin ME, de Groot JF.

J Neurol. 2014 Aug;261(8):1559-64. doi: 10.1007/s00415-014-7292-0. Epub 2014 May 25.

PMID:
24859329
45.

Effects of the Fitkids exercise therapy program on health-related fitness, walking capacity, and health-related quality of life.

Kotte EM, de Groot JF, Winkler AM, Huijgen BC, Takken T.

Phys Ther. 2014 Sep;94(9):1306-18. doi: 10.2522/ptj.20130315. Epub 2014 May 1.

PMID:
24786945
46.

Pregnancy and glial brain tumors.

Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS.

Neuro Oncol. 2014 Sep;16(9):1289-94. doi: 10.1093/neuonc/nou019. Epub 2014 Mar 9.

47.

Update on anti-angiogenic treatment for malignant gliomas.

de Groot JF, Mandel JJ.

Curr Oncol Rep. 2014 Apr;16(4):380. doi: 10.1007/s11912-014-0380-6. Review.

PMID:
24510742
48.

Technique, outcomes, and acute toxicities in adults treated with proton beam craniospinal irradiation.

Barney CL, Brown AP, Grosshans DR, McAleer MF, de Groot JF, Puduvalli V, Tucker SL, Crawford CN, Gilbert MR, Brown PD, Mahajan A.

Neuro Oncol. 2014 Jan;16(2):303-9. doi: 10.1093/neuonc/not155. Epub 2013 Dec 4.

49.

Clinical and prognostic features of adult patients with gangliogliomas.

Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de-Groot JF.

Neuro Oncol. 2014 Mar;16(3):409-13. doi: 10.1093/neuonc/not169. Epub 2013 Dec 4.

50.

Neutrophils promote the malignant glioma phenotype through S100A4.

Liang J, Piao Y, Holmes L, Fuller GN, Henry V, Tiao N, de Groot JF.

Clin Cancer Res. 2014 Jan 1;20(1):187-98. doi: 10.1158/1078-0432.CCR-13-1279. Epub 2013 Nov 15.

Supplemental Content

Loading ...
Support Center